Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KAPPA P PEDDY

Allopathic & Osteopathic Physicians Dermatology

NPI
1558315481
CMS profile
297581
Location
LYNCHBURG, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$793.25

38 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $793.25 38

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $288.11 13
Novartis Pharmaceuticals Corporation $116.74 6
Incyte Corporation $114.03 5
UCB, Inc. $83.54 4
Lilly USA, LLC $59.41 3
Janssen Biotech, Inc. $54.25 2
SUN PHARMACEUTICAL INDUSTRIES INC. $32.74 2
Amgen Inc. $29.48 2
Arcutis Biotherapeutics, Inc. $14.95 1

Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KAPPA P PEDDY

NPI 1558315481 · CMS profile ID 297581

Allopathic & Osteopathic Physicians / Dermatology

LYNCHBURG, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558315481?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KAPPA P PEDDY, NPI 1558315481, CMS profile ID 297581. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558315481?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). KAPPA P PEDDY, NPI 1558315481, CMS profile ID 297581. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558315481?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
KAPPA P PEDDY, NPI 1558315481, CMS profile ID 297581, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1558315481?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

38 matching records · $793.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 38 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–38 of 38.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $22.7312/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143034589 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $18.7012/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152166714 CMS
Incyte Corporation $23.8111/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141257751 CMS
Novartis Pharmaceuticals Corporation $18.2111/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087071440 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $14.0411/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152166716 CMS
ABBVIE INC. $31.8910/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012213 CMS
Lilly USA, LLC $18.0910/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135094740 CMS
ABBVIE INC. $24.1909/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012211 CMS
UCB, Inc. $23.1209/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143034587 CMS
Janssen Biotech, Inc. $27.5708/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078804335 CMS
Incyte Corporation $24.9208/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141290850 CMS
ABBVIE INC. $15.1007/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012209 CMS
Amgen Inc. $14.7407/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117350568 CMS
ABBVIE INC. $29.3807/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012207 CMS
Lilly USA, LLC $19.6107/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135118787 CMS
Novartis Pharmaceuticals Corporation $17.5307/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087071418 CMS
ABBVIE INC. $32.2206/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012205 CMS
Arcutis Biotherapeutics, Inc. $14.9506/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121056613 CMS
Amgen Inc. $14.7406/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117350566 CMS
ABBVIE INC. $26.8405/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012203 CMS
Incyte Corporation $23.2605/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141289926 CMS
ABBVIE INC. $3.0705/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012201 CMS
Lilly USA, LLC $21.7105/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135105373 CMS
Novartis Pharmaceuticals Corporation $19.8704/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087071412 CMS
ABBVIE INC. $25.0704/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012199 CMS
Incyte Corporation $20.6704/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141322899 CMS
UCB, Inc. $23.7504/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143034585 CMS
Janssen Biotech, Inc. $26.6804/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078803657 CMS
ABBVIE INC. $18.0103/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012197 CMS
UCB, Inc. $13.9403/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143034583 CMS
Novartis Pharmaceuticals Corporation $18.8003/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087071404 CMS
ABBVIE INC. $17.5703/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012195 CMS
ABBVIE INC. $15.1603/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012193 CMS
ABBVIE INC. $24.6502/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012191 CMS
Novartis Pharmaceuticals Corporation $20.1602/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087071400 CMS
Incyte Corporation $21.3702/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141288520 CMS
Novartis Pharmaceuticals Corporation $22.1701/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087071396 CMS
ABBVIE INC. $24.9601/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012189 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,052.32 45
PY2020 $141.52 9
PY2022 $791.93 37
PY2023 $1,086.14 48
PY2024 $793.25 38
PY2025 $575.44 25

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $1,667.50 1
PY2023 Principal investigator $8,229.12 3
PY2022 Principal investigator $17,733.75 8
PY2021 Principal investigator $68,639.72 28
PY2020 Principal investigator $44,373.87 16
PY2019 Principal investigator $355,047.00 36

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,840.00 12/18/2019 Non-covered Recipient Entity
The E&R Foundation, Inc.
A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea No dispute reported 06/30/2026 685018229
Principal investigator 1 Endo Pharmaceuticals Inc. $4,951.00 12/10/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639273
Principal investigator 1 Endo Pharmaceuticals Inc. $1,500.00 12/10/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639277
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 11/20/2019 Non-covered Recipient Entity
The E&R Foundation, Inc.
A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea No dispute reported 06/30/2026 685018217
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20,230.00 11/20/2019 Non-covered Recipient Entity
The E&R Foundation, Inc.
A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea No dispute reported 06/30/2026 685018223
Principal investigator 1 Endo Pharmaceuticals Inc. $2,315.00 11/19/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639268
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $19,070.00 10/24/2019 Non-covered Recipient Entity
The E&R Foundation, Inc.
A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea No dispute reported 06/30/2026 685018215
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $29,580.00 10/03/2019 Non-covered Recipient Entity
The E&R Foundation, Inc.
A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea No dispute reported 06/30/2026 685018211
Principal investigator 1 Endo Pharmaceuticals Inc. $8,130.00 09/17/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639265
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $24,020.00 08/28/2019 Non-covered Recipient Entity
The E&R Foundation, Inc.
A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea No dispute reported 06/30/2026 685009995
Principal investigator 1 Aclaris Therapeutics, Inc. $920.00 08/23/2019 Non-covered Recipient Entity
THE E&R FOUNDATION INC
AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO No dispute reported 06/30/2026 700990121
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 08/15/2019 Non-covered Recipient Entity
The E&R Foundation, Inc.
A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea No dispute reported 06/30/2026 685009991
Principal investigator 1 Endo Pharmaceuticals Inc. $4,199.00 08/06/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639257
Principal investigator 1 Endo Pharmaceuticals Inc. $2,378.00 08/06/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639261
Principal investigator 1 Aclaris Therapeutics, Inc. $2,530.00 07/31/2019 Non-covered Recipient Entity
THE E&R FOUNDATION INC
AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO No dispute reported 06/30/2026 700989557
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $36,170.00 07/25/2019 Non-covered Recipient Entity
The E&R Foundation, Inc.
A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea No dispute reported 06/30/2026 685009987
Principal investigator 1 Endo Pharmaceuticals Inc. $5,312.00 07/23/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639253
Principal investigator 1 Endo Pharmaceuticals Inc. $1,950.00 07/16/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 2, OPEN-LABEL EXTENSION STUDY OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639249
Principal investigator 1 Aclaris Therapeutics, Inc. $550.00 06/20/2019 Non-covered Recipient Entity
THE E&R FOUNDATION INC
AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO No dispute reported 06/30/2026 700988805
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35,520.00 06/20/2019 Non-covered Recipient Entity
The E&R Foundation, Inc.
A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea No dispute reported 06/30/2026 685009983
Principal investigator 1 Endo Pharmaceuticals Inc. $17,084.00 06/18/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639245
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $19,710.00 05/24/2019 Non-covered Recipient Entity
The E&R Foundation, Inc.
A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea No dispute reported 06/30/2026 685009979
Principal investigator 1 Endo Pharmaceuticals Inc. $16,738.00 05/14/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639241
Principal investigator 1 Aclaris Therapeutics, Inc. $1,610.00 05/07/2019 Non-covered Recipient Entity
THE E&R FOUNDATION INC
AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO No dispute reported 06/30/2026 700988345
Principal investigator 1 Endo Pharmaceuticals Inc. $20,768.00 04/16/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639239
Principal investigator 1 Aclaris Therapeutics, Inc. $790.00 03/28/2019 Non-covered Recipient Entity
THE E&R FOUNDATION INC
AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO No dispute reported 06/30/2026 700987755
Principal investigator 1 Endo Pharmaceuticals Inc. $21,310.00 03/19/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639235
Principal investigator 1 Aclaris Therapeutics, Inc. $920.00 02/26/2019 Non-covered Recipient Entity
THE E&R FOUNDATION INC
AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO No dispute reported 06/30/2026 700987071
Principal investigator 1 Endo Pharmaceuticals Inc. $23,170.00 02/26/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639231
Principal investigator 1 Endo Pharmaceuticals Inc. $3,000.00 02/11/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY CELLULITE No dispute reported 06/30/2026 686639223
Principal investigator 1 Endo Pharmaceuticals Inc. $2,050.00 02/05/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639219
Principal investigator 1 Aclaris Therapeutics, Inc. $4,170.00 02/04/2019 Non-covered Recipient Entity
THE E&R FOUNDATION INC
AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO No dispute reported 06/30/2026 700986805
Principal investigator 1 Endo Pharmaceuticals Inc. $13,632.00 01/22/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639215
Principal investigator 1 Endo Pharmaceuticals Inc. $1,850.00 01/08/2019 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION INC
A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY No dispute reported 06/30/2026 686639209
Principal investigator 1 Aclaris Therapeutics, Inc. $905.00 01/03/2019 Non-covered Recipient Entity
THE E&R FOUNDATION INC
AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO No dispute reported 06/30/2026 700986201
Principal investigator 1 Aclaris Therapeutics, Inc. $675.00 01/03/2019 Non-covered Recipient Entity
THE E&R FOUNDATION INC
AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO No dispute reported 06/30/2026 700986205